Specimen Atlas
of research peptides.

Synthetic 44-amino-acid GHRH analogue, FDA-approved (2010) for HIV-associated lipodystrophy. Stimulates pulsatile growth hormone release from the anterior pituitary, elevating IGF-1 and reducing visceral adipose tissue by 15–20% over 26 weeks. Distinguished from native GHRH by a trans-3-hexenoic-acid modification that extends plasma half-life from ~7 minutes to ~26 minutes.

Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist with C-18 fatty-acid acylation that enables albumin binding and a ~7-day half-life. FDA-approved 2017 for type 2 diabetes (Ozempic) and 2021 for chronic weight management (Wegovy). The STEP-1 trial showed 14.9% body-weight reduction over 68 weeks at 2.4 mg/week.

First-in-class dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. FDA-approved 2022 for type 2 diabetes (Mounjaro) and 2023 for chronic weight management (Zepbound). The SURMOUNT-1 trial showed 20.9% body-weight reduction at 15 mg/week — the largest weight-loss outcome of any approved pharmacotherapy.

Synthetic 15-amino-acid pentadecapeptide derived from a protective sequence found in human gastric juice (BPC = Body Protection Compound). Stable in simulated gastric conditions and the most extensively studied healing peptide in animal literature. Demonstrates tendon, ligament, muscle, and gastrointestinal mucosa healing across 20+ rodent models. Clinically evaluated under designation PL-14736 in a Phase 2 ulcerative colitis trial.

Endogenous copper-binding tripeptide (Gly-His-Lys) found in human plasma at ~200 ng/mL in young adults, declining sharply with age. Forms a 1:1 complex with Cu(II) to deliver copper to tissues, regulates collagen, elastin, and glycosaminoglycan synthesis, and triggers anti-inflammatory + regenerative gene programs. Widely used topically and via SQ injection for skin rejuvenation, wound healing, and hair regrowth.

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed at the Saint Petersburg Institute of Bioregulation and Gerontology as the active analog of epithalamin, a natural pineal extract. Khavinson et al. demonstrated telomerase-activating and telomere-elongating activity in human somatic cells. Long-term safety + efficacy data are dominated by Russian-language literature; Western RCTs are sparse. Frequently used anecdotally for longevity and sleep regulation.

16-amino-acid mitochondrial-encoded peptide (mitokine) translated from the 12S rRNA short open reading frame. Activates AMPK via folate-cycle inhibition, increasing fatty acid oxidation, glucose tolerance, and mitochondrial biogenesis. Endogenous levels decline with age and rise with exercise — frequently described as an exercise-mimetic. No completed human RCT to date; first MOTS-c-analog Phase 1a/1b (CB4211) completed 2021.

Pentapeptide growth-hormone-releasing peptide (GHRP) that selectively activates the ghrelin receptor (GHS-R1a) on the anterior pituitary, eliciting GH release without the cortisol or prolactin elevation characteristic of earlier GHRPs. Originally characterised by Raun et al. (1998); preferred GHRP partner for GHRH analogues like tesamorelin and CJC-1295.

Investigational triple-receptor agonist of GLP-1, GIP, and glucagon receptors developed by Eli Lilly. The Phase 2 trial (Jastreboff et al., NEJM 2023) demonstrated 24.2% body-weight reduction at 12 mg over 48 weeks — the largest weight-loss effect of any peptide tested in obesity. Phase 3 trials ongoing as of 2026.

Synthetic 17-amino-acid fragment of human thymosin β4 (TMSB4X), itself a 43-residue actin-sequestering protein abundant in platelets, white blood cells, and many other tissues. Promotes endothelial cell migration, blood vessel development, and accelerated wound re-epithelialization across animal models and Phase 2 trials. Often paired with BPC-157 for tendon / ligament / muscle repair.

Tripeptide (Lys-Pro-Val) corresponding to the C-terminus of α-melanocyte- stimulating hormone (α-MSH). Retains the anti-inflammatory and immune- modulatory properties of full α-MSH without the pigmentation effects. Multiple animal studies support efficacy in inflammatory bowel disease, acne, and atopic dermatitis. Often paired orally / topically with BPC-157 for gut and skin protocols.

Synthetic tetrapeptide (Glu-Asp-Arg) developed at the Saint Petersburg Institute of Bioregulation and Gerontology. Russian literature reports neuroprotective and antioxidant effects, particularly in age-related cognitive decline. Limited Western RCT data. Frequently used anecdotally for cognitive support and longevity, often in combination with Epitalon.